Pinealon and Other Peptides
With growing interest in peptide-based interventions, Pinealon is often compared with several well-known peptides, including Epitalon, Semax, Cerebrolysin, SS-31, and Tesamorelin. While these compounds are frequently discussed in the same contexts, they differ significantly in molecular structure, biological targets, proposed mechanisms of action, and areas of scientific research.
Pinealon vs Epitalon
Pinealon and Epitalon are bioregulatory peptides developed by Vladimir Khavinson and his associates. Both are frequently discussed in the context of healthy ageing and longevity research. Despite these similarities, however, they are distinct molecules. Pinealon is a tripeptide composed of glutamic acid, aspartic acid, and arginine (Glu-Asp-Arg; EDR), whereas Epitalon is a tetrapeptide consisting of alanine, glutamic acid, aspartic acid, and glycine (Ala-Glu-Asp-Gly) (1,2).
Research on Pinealon has primarily focused on neuroprotection, cognitive function, oxidative stress regulation, neuronal survival, and age-related neurological changes (3–8). Experimental studies have shown that Pinealon reduces reactive oxygen species (ROS) levels, improves neuronal viability, increases serotonin expression, and protects nerve cells from various forms of cellular stress (4–8).
Conversely, research on Epitalon mainly focuses on the biology of ageing, telomerase activity, melatonin regulation, circadian rhythm function, and mechanisms related to longevity. Although both peptides are classified as geroprotective bioregulators, Pinealon is generally perceived as a peptide with a more neurocentric effect, whereas Epitalon is more often associated with systemic anti-ageing research and pineal gland function.
As both peptides can interact with different biological pathways, some researchers and users of peptides see Pinealon and Epithalon as potentially complementary compounds. However, controlled clinical studies evaluating their concomitant use are very limited, and no large-scale human trials have been conducted to date confirming the safety or efficacy of such an approach.
Pinealon vs Semax
Pinealon and Semax are often compared as both have been studied for neuroprotection and cognitive support. However, they belong to entirely different peptide families.
Pinealon is a short bioregulatory tripeptide (Glu-Asp-Arg), while Semax is a synthetic analogue of the adrenocorticotropic hormone ACTH(4-10), developed in Russia for neurological applications (9,10).
The available data suggest that Pinealon exerts many of its biological effects through the regulation of oxidative stress, epigenetic mechanisms, modulation of gene expression, interaction with serotonin-related pathways, and by supporting neuronal survival (4–8). In contrast, research on Semax has mainly focused on neurotrophic activity, modulation of neurotransmitter systems, neuroprotection after ischemic damage, and improvement of cognitive functions (9,10).
Although both peptides are being investigated for brain health and cognitive function, research on Semax primarily highlights neurotrophic and neurotransmitter-related effects, while research on Pinealon focuses more on cell protection, aging biology, reduction of oxidative stress, and epigenetic regulation.
Currently, no direct clinical trials comparing Pinealon and Semax in humans have been conducted.
Pinealon vs Cerebrolysin
Cerebrolysin differs significantly from Pinealon in both composition and complexity. Pinealon consists of a single synthetic tripeptide, whereas Cerebrolysin is a complex mixture of low-molecular-weight neuropeptides and amino acid fragments derived from porcine brain tissue.
Research into Cerebrolysin has mainly focused on stroke recovery, traumatic brain injury, vascular dementia, and Alzheimer's disease. In contrast, research into Pinealon has primarily concerned neuroprotection, oxidative stress resistance, cognitive function, and healthy ageing (3–8).
The key difference between these compounds is the scale of available clinical data. Cerebrolysin has been evaluated in significantly larger clinical trial programmes than Pinealon. Data for Pinealon remain limited and are primarily derived from preclinical studies and relatively small clinical trials.
Although both compounds are investigated for neuroprotective properties, they act via different biological mechanisms and should not be treated as interchangeable.
Pinealon vs SS-31
SS-31 (elamipretide) is a mitochondria-targeted peptide developed to protect mitochondrial function and limit oxidative damage in cells. In contrast to Pinealon, which appears to affect gene expression, neuronal survival, serotonin synthesis, and cell signalling pathways, SS-31 primarily acts on mitochondrial membranes and cellular bioenergetics.
Both peptides have been investigated for their ability to reduce oxidative stress. Pinealon has been shown to limit reactive oxygen species accumulation and reduce cellular damage under oxidative stress conditions (4,5), whereas studies on SS-31 have focused on improving mitochondrial efficiency and limiting damage resulting from their dysfunction.
Currently, no direct studies have been conducted comparing Pinealon and SS-31.
Pinealon vs. Tesamorelin
Pinealon and Tesamorelin belong to completely different peptide categories and have been studied for entirely different biological purposes.
Pinealon is a neuroregulatory bioregulatory tripeptide, primarily studied in the context of neuroprotection, cognitive function, oxidative stress regulation, and healthy ageing (3–8). Tesamorelin, on the other hand, is a growth hormone-releasing hormone (GHRH) analogue that stimulates the secretion of endogenous growth hormone and increases the production of insulin-like growth factor-1 (IGF-1).
Research into Tesamorelin has primarily focused on the reduction of visceral fat, body composition, metabolic health, and growth hormone-related physiology. In contrast, research into Pinealon has focused on neuronal protection, learning and memory processes, serotonin expression, and cellular mechanisms related to ageing.
Due to these significant mechanistic differences, the question of „Tesamorelin vs. Pinealon” is not a direct comparison. Both peptides are studied for different scientific purposes and affect distinct physiological systems.
General Scientific Perspective
Pinealon stands out among many frequently discussed peptides due to its combination of neuroprotective, antioxidant, epigenetic, and geroprotective properties. Current data suggests that Pinealon may support neuronal survival, reduce oxidative stress, influence serotonin-related pathways, and regulate cellular functions associated with ageing and neuroprotection.
However, direct clinical trials comparing Pinealon with other peptides remain very limited. Consequently, definitive conclusions regarding the relative efficacy, safety, or advantages of individual compounds cannot currently be drawn. Additional, well-designed human studies are needed to better characterise the similarities and differences between these peptides.
Disclaimer
The content is of an educational and informational nature only and should not be interpreted as medical advice, diagnosis, treatment, or professional recommendation. Pinealon, Epitalon, Semax, Cerebrolysin, SS-31, and Tesamorelin differ significantly in their structure, mechanisms of action, and areas of scientific research. Pinealon has not been approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), or most other regulatory bodies for the treatment of neurological disorders, cognitive impairments, age-related conditions, or any other medical indications. A significant portion of the available data comes from preclinical studies and limited human trials. Further well-designed clinical trials are necessary to better determine the efficacy, safety, and long-term effects of these peptides, and to establish whether there are significant differences between them in clinical settings.
References
- Pinealon (EDR peptide) chemistry and composition data.
Wikipedia: https://en.wikipedia.org/wiki/Pinealon - Fedoreyeva, L. I., Kireev, I. I., Khavinson, V. K., & Vanyushin, B. F. (2011). Penetration of short fluorescence-labelled peptides into the nucleus in HeLa cells and in vitro, specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow), 76(11), 1210–1219. https://doi.org/10.1134/S0006297911110022
Journal Link: https://link.springer.com/article/10.1134/S0006297911110022 - Meshchaninov, V. N., Tkachenko, E. L., Zharkov, S. V., Gavrilov, I. V., & Katyreva, Y. E. (2015). The effect of synthetic peptides on the ageing of patients with chronic polymorbidity and organic cerebral syndrome in remission. Advances in Gerontology, 28(1), 62–67.
PubMed: https://pubmed.ncbi.nlm.nih.gov/26390612/ - Khavinson, V., Ribakova, Y., et al. (2011). Pinealon increases cell viability by suppressing free radical levels and activating proliferative processes.. Rejuvenation Research, 14(5), 517–523. https://doi.org/10.1089/rej.2011.1172
Journal Link: https://journals.sagepub.com/doi/abs/10.1089/rej.2011.1172 - Arutjunyan, A. V., Kozina, L. S., Stvolinsky, S. L., Bulygina, E. R., Mashkina, A. P., & Khavinson, V. K. (2012). Pinealon protects rat pups from prenatal hyperhomocysteinemia. International Journal of Peptides, 2012, 109757. https://doi.org/10.1155/2012/109757
PubMed: https://pubmed.ncbi.nlm.nih.gov/22567179/
PMC Full Text: https://pmc.ncbi.nlm.nih.gov/articles/PMC3342713/ - Khavinson, V. K., Lin’kova, N. S., Tarnovskaya, S. I., Umnov, R. S., Elashkina, E. V., & Durnova, A. O. (2014). Short peptides stimulate serotonin expression in cells of the cerebral cortex. Bulletin of Experimental Biology and Medicine, 157(1), 77–80. https://doi.org/10.1007/s10517-014-2496-y
PubMed: https://pubmed.ncbi.nlm.nih.gov/24909721/ - Kraskovskaya, N. A., Kukanova, E. O., Lin’kova, N. S., Popugaeva, E. A., & Khavinson, V. K. (2017). Tripeptides restore the number of neuronal spines in conditions of in vitro modelled Alzheimer’s disease. Bulletin of Experimental Biology and Medicine, 163(4), 547–550. https://doi.org/10.1007/s10517-017-3847-2
PubMed: https://pubmed.ncbi.nlm.nih.gov/28853087/ - Khavinson, V., Ilina, A., Kraskovskaya, N., Linkova, N., Kolchina, N., Mironova, E., Erofeev, A., & Petukhov, M. (2021). Neuroprotective effects of tripeptides—epigenetic regulators in a mouse model of Alzheimer’s disease. Pharmaceuticals, 14(6), 515. https://doi.org/10.3390/ph14060515
Journal Link: https://www.mdpi.com/1424-8247/14/6/515 - Tsai, S. J. (2007). Semax, an analogue of adrenocorticotropin (4–10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome.. Medical Hypotheses, 68(5), 1144–1146. https://doi.org/10.1016/j.mehy.2006.07.017
PubMed: https://pubmed.ncbi.nlm.nih.gov/16996699/ - Dolotov, O. V., Karpenko, E. A., Inozemtseva, L. S., Seredenina, T. S., Levitskaya, N. G., Rozyczka, J., Dubynina, E. V., Novosadova, E. V., Andreeva, L. A., Alfeeva, L. Y., Kamensky, A. A., Grivennikov, I. A., Myasoedov, N. F., & Engele, J. (2006). Semax, an analogue of ACTH(4–10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1), 54–60. https://doi.org/10.1016/j.brainres.2006.07.108
PubMed: https://pubmed.ncbi.nlm.nih.gov/16996037/